Cell Line Data Sheet for CHLA-259

Disease:	Anaplastic Medulloblastoma
Phase of Therapy:	Diagnosis
Treatment:	None
Disease Stage:	NA
Gender:	Male
Age at diagnosis:	168 months
Race:	Hispanic
Age at sample collection:	168 months
Source of Culture:	Solid tumor (parietal lobe)
Primary Tumor Site:	Posterior fossa (4th ventricle)
Date Established:	May 2001
MYCN Patient:	Amplified
MYCN Cell line:	Relative copy number - NA
TH mRNA:	NA
p53 functionality:	Functional
Telomere Mechanism:	NA
ALK:	NA
RNAseq:	NA
WES:	NA

Growth Conditions:	Please see Protocols section at https://www.cccells.org/protocols.php 5% CO_2, 20% O_2, 37.0°C
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time:	76 hours
Growth Properties:	Adherent monolayer and small population of suspended and attached clumps
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	None

All cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.

Cell Line Data Sheet for CHLA-259

Cell Line Name: **CHLA-259**

References:

1. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology. Epub, 2011. PubMed ID: 22120608

Cell Line Data Sheet for CHLA-259

Cell Line Name: **CHLA-259**

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)